



The Royal College of Radiologists

63 LINCOLN'S INN FIELDS, LONDON WC2A 3JW
T. +44(0)20 7405 1282 enquiries@rcr.ac.uk
www.rcr.ac.uk

Dr Rosie Benneyworth
Vice Chair
National Institute for Health and Care Excellence
10 Spring Gardens
London SW1A 2BU

11 October 2017

Dear Dr Benneyworth

Appeal against NICE Final Appraisal Determination on “Intrabeam radiotherapy system for adjuvant treatment of early breast cancer”

Thank you for your letter dated 27 September 2017.

The thrust of our appeal is that the factual error led to information around potential increased mortality not being taken into account in the overall decision, particularly in the economic and statistical model that supported further use of the technology.

Our argument is that some patients randomised in the Targit trial (and thus who would now be considered for Intrabeam) were at increased risk of death from local recurrence. The model used in the appraisal showed that at five years local recurrence might be different, but only accounted for in terms of mastectomy, rather than potentially dying from metastatic breast cancer. The financial argument that Intrabeam was no worse (when some women would be at risk of significant lines of therapy for breast cancer relapse) stemmed from the factual error.

We think the correct facts would impact on model used so might change outcome if the error is corrected or have led to different decision in the first place.

We absolutely want the error changed but the process flowing from the error (and the fact that the error was not corrected through extant processes as you indicate could have been possible) is what we are appealing.

We have no further points to raise to those we already have at this time, and would welcome the opportunity to make oral submissions at an appeal hearing.

Yours sincerely

pp.

Dr Jeanette Dickson
Vice-President, Clinical Oncology

For and on behalf of:

[REDACTED], Independent Cancer Patients' Voices

[REDACTED] Royal College of Physicians.